View this email in your browser
February 2017
Study compares docetaxel with or without nivolumab in advanced NSCLC
A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in treating lung cancer patients whose disease worsened after initial response to immunotherapy. The randomized phase II study, known as HCRN LUN15-233, involves docetaxel (also known as Taxotere®) with or without nivolumab (also known as Opdivo®). Nasser Hanna, MD, (pictured) is leading the study, along with co-investigators Laura Lourdes, MD; Shadia Jalal, MD; and Lawrence Einhorn, MD.

Read more.
HCRN chairman launches third "Reps for Research" fundraising challenge
For the third consecutive year, Hoosier Cancer Research Network chairman Christopher A. Fausel, PharmD, is combining his passion for investigator-initiated research with his annual participation in the Arnold Sports Festival Pump & Run 5K in Columbus, Ohio. Fausel has participated in the annual strength and endurance event for several years, and is inviting pledges in support of Hoosier Cancer Research Network (HCRN) for every bench press “rep” he completes (maximum of 30) during the event on Sunday, March 5, 2017.

Donations received will directly support investigator-initiated research, which is central to HCRN’s vision and mission.

Read more  •  Make a pledge
Ansari reflects on success and change in community oncology
Rafat H. Ansari, M.D., F.A.C.P., a medical oncologist/hematologist at Michiana Hematology Oncology, is one of the six founding members of Hoosier Cancer Research Network. In this personal profile, Dr. Ansari shares his perspective on the early years of Hoosier Oncology Group, and the opportunity that HCRN provides to community-based oncology practices who want to conduct research.

Read more.
HCRN seeks student interns
Three graduate student positions now open
Hoosier Cancer Research Network (HCRN), a nonprofit cancer research organization in Indianapolis, is seeking graduate student interns for the 2017-2018 academic year. Training will be scheduled for May 2017.
 
Three internship positions are currently available: two general internships, and one communications internship. All positions will require 20-25 hours per week.

See job description.

Applicants should send resumes by email to Pam Griffin at pgriffin@hoosiercancer.org with “Student Internship” in the subject line. Please indicate whether you are applying for a general internship or a communications internship.
Studies in Development
  • HER2+ breast (DFCI)
  • Recurrent breast (U Penn)
  • TNBC (UCSF)
  • Bladder (Johns Hopkins)
  • Bladder (Mount Sinai)
  • Bladder (NYU)
  • Germ cell (IUSCC)
  • Hepatic colorectal (Rutgers)
  • Hepatocellular (UNC)
  • Kidney (Georgetown)
  • Urothelial (2 studies)
    (Mount Sinai)
  • Kidney (UAB)
  • Melanoma (Mayo)
  • Melanoma (Nebraska)
  • NSCLC (IUSCC)



For more information:
Contact Anita Borek at
aborek@hoosiercancer.org
or call 317-634-5842, ext. 48.


Open to Accrual
Closed to Accrual
Completed Studies
Featured Members

Each month, HCRN highlights a member site that has actively participated in our trials. Learn more about our featured members for January and February:



City of Hope (Duarte, Calif.)




Cleveland Clinic Taussig Cancer Institute (Cleveland, Ohio)

Thank you to these and all our members for helping us fulfill our mission.
 
© 2017 Hoosier Cancer Research Network, All rights reserved.
500 N. Meridian Street, Suite 100, Indianapolis, IN 46204  |  P: 317-921-2050  |  www.hoosiercancer.org
unsubscribe from this list    update subscription preferences